Dr. Neal Muni is an accomplished life sciences executive with 25 years of industry experience as an operator, investor, and advisor to multiple biotechnology and pharmaceutical companies, leveraging unique insights gained through a career spanning industry, healthcare investment banking, the FDA, and clinical care.
Dr. Muni currently serves as the Managing Director of RTK Group, a biopharmaceutical advisory and investment fund. As part of his operating and advisory roles through RTK Group, Dr. Muni serves as Advisor and Chief Medical Officer of Unravel Biosciences, Advisor and Partner at Romeg Therapeutics, Board Member of BridgeHealth Pharmaceuticals and Independent Board Director of HDAX Therapeutics
Prior to RTK Group, Dr. Muni served as the CEO of Azurity Pharmaceuticals, a commercial-stage pharmaceutical company focused on developing therapeutics for patients with high unmet need, including children and the elderly. During his tenure as CEO, Dr. Muni achieved a successful investor exit with company sale to private equity upon receiving FDA approval of the company’s lead program.
Prior to Azurity, Dr. Muni served as the Head of Corporate Strategy at Sunovion Pharmaceuticals. Prior to that, Dr. Muni was an engagement manager at the healthcare investment bank Leerink Swann. Prior to Leerink, he was a Medical Officer in the Division of Cardiovascular Devices at the FDA.
Dr. Muni maintains faculty appointments at Harvard Medical School and the Brigham and Women’s Hospital, where he continues to practice inpatient medicine and teach medical residents and students several weeks per year as a staff Hospitalist. Dr. Muni also dedicates time mentoring the next generation of biotech entrepreneurs through his affiliations with Harvard University’s Wyss Institute for Biologically Inspired Engineering, MassBio’s Drive Accelerator Program, and the University of Toronto’s Creative Destruction Lab. Dr. Muni also serves on the Board of Trustees of Winchester Hospital, an affiliate of Beth Israel Lahey Health.
Dr. Muni received his MD as well as Master of Science in Public Health (biostatistics) from the Tulane University School of Medicine, and a BA in Business Economics and B.Sc. in Biochemistry from Brown University.
At the Wyss Institute, Neal is a member of the Wyss Mentor Hive who specializes in therapeutics, FDA regulation, clinical development, Investigational New Drug-enabling studies, and commercialization. As a mentor, Neal works closely with Wyss project teams and collaborates on technology development, partnering, and company formation.
The Wyss Mentor Hive is a mentoring program that invites investors and business professionals with significant early stage translational experience, clinical and regulatory experts in driving therapeutic and device development, and serial entrepreneurs with a track record of success to work closely with Wyss entrepreneur teams on startup formation and technology commercialization. Mentors provide feedback to founders and entrepreneurs, while also demonstrating commitment and leadership in the Wyss innovation community.